Abstract
OBJECTIVE: In a prospective, double-blind, randomized in vitro fertilization (IVF) trial, subjects in the control group were treated with a rFSH/GnRH antagonist regimen. The North American (NA) cohort comprised 54% of subjects, providing an opportunity to assess the impact of individualized care (rFSH dose, coasting, timing of human chorionic gonadotropin [hCG] trigger) on clinical outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
